Opus Genetics (IRD) Net Income towards Common Stockholders (2010 - 2026)
Opus Genetics (IRD) posted quarterly Net Income towards Common Stockholders of -$65.5 million for Q1 2026, down 699.79% year-over-year from $10.9 million in Q1 2025, and down 972.76% quarter-over-quarter from -$6.1 million in Q4 2025.
Opus Genetics (IRD) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Net Income towards Common Stockholders for 17 consecutive years, with -$65.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 699.79% year-over-year to -$65.5 million; the TTM figure through Mar 2026 stood at -$96.5 million (down 64.65% YoY), while the FY2025 annual figure was -$39.2 million, up 31.9% from the prior year.
- Net Income towards Common Stockholders slipped to -$65.5 million in Q1 2026 per IRD's latest filing, from -$6.1 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $33.9 million in Q4 2022 and bottomed at -$65.5 million in Q1 2026.
- Historically, Net Income towards Common Stockholders has averaged -$9.1 million across 5 years, with a median of -$6.6 million in 2022.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders surged 637.64% — and 2026, when it plunged 699.79%.
- Opus Genetics' Net Income towards Common Stockholders stood at $33.9 million in 2022, then slumped by 114.13% to -$4.8 million in 2023, then slumped by 632.74% to -$35.1 million in 2024, then jumped by 82.61% to -$6.1 million in 2025, then plunged by 972.76% to -$65.5 million in 2026.
- Business Quant data shows IRD's Net Income towards Common Stockholders at -$65.5 million in Q1 2026, -$6.1 million in Q4 2025, and -$17.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - | -8.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.10 Mn |
| Mar 31, 2026 | -65.54 Mn |
| Dec 31, 2025 | -6.11 Mn |
| Sep 30, 2025 | -17.45 Mn |
| Jun 30, 2025 | -7.42 Mn |
| Mar 31, 2025 | -8.19 Mn |
| Dec 31, 2024 | -35.14 Mn |
| Sep 30, 2024 | -7.53 Mn |
| Jun 30, 2024 | -7.77 Mn |
| Mar 31, 2024 | -7.11 Mn |
| Dec 31, 2023 | -4.80 Mn |
| Sep 30, 2023 | 5.56 Mn |
| Jun 30, 2023 | -4.96 Mn |
| Mar 31, 2023 | -5.79 Mn |
| Dec 31, 2022 | 33.94 Mn |
| Sep 30, 2022 | -4.53 Mn |
| Jun 30, 2022 | -4.93 Mn |
| Mar 31, 2022 | -6.60 Mn |
| Dec 31, 2021 | -6.31 Mn |
| Sep 30, 2021 | -4.23 Mn |